Toggle light / dark theme

Is the longevity industry the healthtech investment trend?

Forbes contributor and finance expert Richard Eisenberg discusses with Taimur Hyat, Chief Strategy Officer at Prudential Financial’s investment arm ($963 billion of funds under management).

Hyat shared his views on investinginto the ageing industry. He noted ‘the first wave of tech and apps was designed with millennials in mind — pizza delivery and Uber. The next wave of platforms and technology will be designed with the needs of the elderly in mind.

Read more

Summary: Treatability of cancer was raised to over 80% by a new intelligent system that sifts through massive genetic datasets to pinpoint targets for cancer treatment, say these scientists. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

Scientists in Singapore have discovered a significantly improved way to treat cancer by listening to many different computer programs rather than just one.

Their new computer program reaches a consensus on how to treat a specific tumor, and it is significantly more accurate than existing predictive methods. The system isolates the Achilles heel of each individual tumor, helping doctors to choose the best treatment.

Read more

Summary: UCSD researchers just reported that a strain of bacteria prevents skin cancer. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

The human microbiome is emerging a major player in protecting our health and researchers at the University of California San Diego (UCSD) just reported that some strains of skin bacteria safeguard against cancer.

Leading the study is Richard Gallo, MD, Ph.D., a Distinguished Professor and the chair of the Department of Dermatology at the UCSD School of Medicine, who says.

Read more

The longest-lived bats—those belonging to the Myotis genus—may have their telomeres to thank for their slow aging process, according to a study published yesterday (Feb 7) in Science Advances.

“In the longest-lived species of bats telomeres don’t shorten with age,” study coauthor Emma Teeling, a professor of biology and environmental science at University College Dublin, tells The Irish Times. “Whereas in other bats species, humans and other animals they do, causing the age-related breakdown of cells that over the course of a lifetime can drive tissue deterioration and ultimately death.”

Teeling and her colleagues conducted wing biopsies on close to 500 bats of four different species at field sites across Europe. Tissue analysis revealed that while the telomeres shortened with age in two bat species, Rhinolophus ferrumequinum and Miniopterus schreibersii, no such change occurred in species belonging to Myotis, the bat genus with the greatest longevity.

Read more

A potential new biomarker of aging has been discovered by researchers. This substance, found in urine, indicates oxidative damage that could be used to determine how much someone has aged biologically.

Why do we need biomarkers of ageing?

It is important for us to develop accurate and reliable biomarkers of aging, as these can show us how much we have aged biologically rather than chronologically. If we know how we are aging on a biological level, it can help to inform our healthcare strategy.

Read more

BioViva is a platform to expedite the development of drugs and treatments that affect human healthspan. To achieve this goal BioViva has developed a comprehensive set of biomarkers of aging, which include molecular, physiological, anatomical, clinical, and qualitative markers. BioViva also collaborates with clinicians, biomedical scientists, and statisticians to develop innovative protocols for adaptive clinical trials for gene and cells therapies. Finally, BioViva has built a bioinformatics pipeline to analyze the data generated from the biomarkers of aging in human trials, and validate the treatments that are effective for treating the aging process.

BioViva has recently partnered with a paid-for clinical trial company Integrated Health Systems (IHS). IHS connects doctors with patients who want to take part in paid-for clinical trials. During our collaboration with IHS they will utilize our adaptive clinical trial protocols to conduct gene and cell therapy trials. All patients will undergo pre- and post testing using BioViva’s comprehensive biomarkers of aging platform. Treatment efficacy, and patient well being will be assessed using our bioinformatics pipeline…

The goal of BioViva is to accelerate the development of products that will effectively, and cost-efficiently treat biological aging. Our platform is designed to provide expedited and reliable feedback to our clinical and manufacturing partners, so that they may rapidly iterate their products and services to help patients improve the quality and quantity of life.

Read more